Jump to section
IdentificationPharmacologyInteractionsReferencesTrialsEconomicsPropertiesSpectraTaxonomyUbidecarenone
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Name
- Ubidecarenone
- Accession Number
- DB09270
- Type
- Small Molecule
- Groups
- Experimental
- Description
Ubidecarenone, also known as Coenzyme Q10, is a 1,4-benzoquinone, where Q refers to the quinone chemical group, and 10 refers to the number of isoprenyl chemical subunits in its tail. This oil-soluble, vitamin-like substance is present in most eukaryotic cells, primarily in the mitochondria. It is a component of the electron transport chain and participates in aerobic cellular respiration, generating energy in the form of ATP. Ninety-five percent of the human body’s energy is generated this way. Therefore, those organs with the highest energy requirements—such as the heart, liver and kidney—have the highest CoQ10 concentrations. There are three redox states of CoQ10: fully oxidized (ubiquinone), semiquinone (ubisemiquinone), and fully reduced (ubiquinol). The capacity of this molecule to exist in a completely oxidized form and a completely reduced form enables it to perform its functions in the electron transport chain, and as an antioxidant, respectively.
- Structure
Structure for DB09270 (Ubidecarenone)
- Synonyms
- Coenzyme Q-10
- Coenzyme Q10
- External IDs
- API 31510 / API-31510 / NSC-140865
- Product Ingredients
Ingredient UNII CAS InChI Key Coenzyme q10, (2z)- U705VLF0VW 65085-29-2 ACTIUHUUMQJHFO-LLOLQPSSSA-N - Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Co-enzyme Q-10 Capsules Capsule 30 mg Oral Ashbury Research Corporation Not applicable Not applicable Canada 
Co-q10 (ubiquinone) Capsule 60 mg Oral Abundance Naturally Ltd Not applicable Not applicable Canada Q-gel Coenzyme Q10 Capsule 15 mg Oral T & T Nutrition Inc. Not applicable Not applicable Canada Watkins Coq10 Tablet 60 mg Oral Watkins Incorporated Not applicable Not applicable Canada - Over the Counter Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Acti-ubiquinone 50 Cap 50mg Capsule 50 mg Oral Acti Form Ltd. 1991-12-31 2005-03-21 Canada Biogard Ubiquinone Cap 30mg Capsule 30 mg Oral Sisu Inc. 1994-12-31 2001-08-01 Canada Biomed Co Q 10 Capsule 100 mg Oral Sisu Inc. 1998-02-11 2008-07-25 Canada Cell Tech Coenzyme Q10 - Cap 30mg Capsule 30 mg Oral Cell Tech 1996-11-12 2000-10-05 Canada Cellsparc 360 Capsule 60 mg Oral Aim International, Inc. 1998-07-29 2008-09-03 Canada Co Q 10 - 50mg Cap Capsule 50 mg Oral Albi Naturals 1994-12-31 2008-07-17 Canada Co-enzyme Q-10 Capsule 30 mg Oral Holista Health (Canada) Inc. 1996-12-31 2002-08-06 Canada Co-enzyme Q-10 Capsule 30 mg Oral Seroyal International Inc. 1995-12-31 2008-07-14 Canada Co-enzyme Q10 100mg Capsule 100 mg Oral Natural Factors Nutritional Products Ltd. 1999-07-12 2009-09-28 Canada Co-enzyme Q10 30mg Capsules Capsule 30 mg Oral Alive Vitamins 1998-07-27 2005-07-04 Canada - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Biosculpt Ubidecarenone (1.5 mg) + Choline bitartrate (0.3 mg) + Chromium (40 mcg) + Inositol (0.3 mg) + Calcium pantothenate (60 mg) + Pyridoxine hydrochloride (4 mg) Solution Oral Maxion Nutrition Corp. 2002-06-10 2004-07-20 Canada Co-q10 and Vitamin E Ubidecarenone (100 mg) + Vitamin E (300 unit) Capsule Oral Biomed International Products Corp. 2003-10-01 2006-06-29 Canada Coenzyme Q10 Isotonix Vitamin and Mineral Supplement Ubidecarenone (30.03 mg) + Potassium (32.43 mg) + Riboflavin (0.9 mg) + Vitamin E (60.06 mg) Powder Oral Market America 2002-06-04 2008-09-04 Canada Daily Supplement Packs Ubidecarenone (30 mg) + Cyanocobalamin (125 mcg) + Folic Acid (0.4 mg) + Magnesium (150 mg) + Pyridoxine (50 mg) + Vitamin E (400 unit) Capsule Oral Wn Pharmaceuticals Ltd. 2002-10-18 2005-08-15 Canada Formula B Ubidecarenone (30 mg) + Magnesium (200 mg) + Pyridoxine (25 mg) + Thiamine (25 mg) + Vitamin C (250 mg) + Zinc (30 mg) Capsule Oral Balance Plus, Inc. 2000-04-19 2004-08-17 Canada Formula Dpr Ubidecarenone (30 mg) + Riboflavin (30 mg) Capsule Oral Balance Plus, Inc. 2000-03-08 2004-08-17 Canada Formula Statin Support Ubidecarenone (30 mg) + Cyanocobalamin (50 mcg) + Magnesium (200 mg) + Pantothenic acid (50 mg) + Pyridoxine (50 mg) Capsule Oral Balance Plus, Inc. 2000-04-19 2004-08-17 Canada L.I.P. Complex Ubidecarenone (10 mg) + Beta carotene (625 unit) + Cholecalciferol (200 unit) + Chromium (200 mcg) + Cyanocobalamin (50 mcg) + Folic Acid (0.4 mg) + Magnesium (50 mg) + Pyridoxine hydrochloride (50 mg) + Vitamin A palmitate (1875 unit) + Calcium ascorbate (100 mg) + Vitamin E (75 unit) Tablet Oral Abundance Marketing Ltd. 2000-12-06 2004-06-30 Canada N.E.U. Complex Ubidecarenone (10 mg) + Cholecalciferol (400 unit) + Cyanocobalamin (50 mcg) + Folic Acid (0.4 mg) + Nicotinamide (25 mg) + Pyridoxine hydrochloride (10 mg) + Riboflavin (10 mg) + Thiamine Hydrochloride (10 mg) + Calcium ascorbate (150 mg) + Vitamin E (60 unit) Tablet Oral Abundance Marketing Ltd. 2000-12-04 2004-06-30 Canada N.U.T. Complex Ubidecarenone (10 mg) + Chromium (200 mcg) + Cyanocobalamin (50 mcg) + Folic Acid (0.4 mg) + Magnesium (100 mg) + Manganese (5 mg) + Potassium (50 mg) + Pyridoxine hydrochloride (15 mg) + Calcium ascorbate (100 mg) + Zinc (10 mg) Tablet Oral Abundance Marketing Ltd. 2000-12-06 2004-06-30 Canada - Categories
- UNII
- EJ27X76M46
- CAS number
- 303-98-0
- Weight
- Average: 863.3435
Monoisotopic: 862.683911368 - Chemical Formula
- C59H90O4
- InChI Key
- ACTIUHUUMQJHFO-UPTCCGCDSA-N
- InChI
- InChI=1S/C59H90O4/c1-44(2)24-15-25-45(3)26-16-27-46(4)28-17-29-47(5)30-18-31-48(6)32-19-33-49(7)34-20-35-50(8)36-21-37-51(9)38-22-39-52(10)40-23-41-53(11)42-43-55-54(12)56(60)58(62-13)59(63-14)57(55)61/h24,26,28,30,32,34,36,38,40,42H,15-23,25,27,29,31,33,35,37,39,41,43H2,1-14H3/b45-26+,46-28+,47-30+,48-32+,49-34+,50-36+,51-38+,52-40+,53-42+
- IUPAC Name
- 2-[(2E,6E,10E,14E,18E,22E,26E,30E,34E)-3,7,11,15,19,23,27,31,35,39-decamethyltetraconta-2,6,10,14,18,22,26,30,34,38-decaen-1-yl]-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione
- SMILES
- COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O
Pharmacology
- Indication
- Not Available
- Structured Indications
- Not Available
- Pharmacodynamics
- Not Available
- Mechanism of action
- Not Available
- Absorption
- Not Available
- Volume of distribution
- Not Available
- Protein binding
- Not Available
- Metabolism
- Not Available
- Route of elimination
- Not Available
- Half life
- Not Available
- Clearance
- Not Available
- Toxicity
Acute oral LD50 (rat) – greater than 4,000 mg/Kg
- Affected organisms
- Humans and other mammals
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
Drug Interaction Drug group Abafungin The risk or severity of adverse effects can be increased when Abafungin is combined with Ubidecarenone. Investigational Acenocoumarol Ubidecarenone may decrease the anticoagulant activities of Acenocoumarol. Approved Acetaminophen The serum concentration of Ubidecarenone can be increased when it is combined with Acetaminophen. Approved Acetazolamide The serum concentration of Ubidecarenone can be increased when it is combined with Acetazolamide. Approved, Vet Approved Acipimox Acipimox may increase the myopathic rhabdomyolysis activities of Ubidecarenone. Approved Albaconazole The risk or severity of adverse effects can be increased when Albaconazole is combined with Ubidecarenone. Investigational Aldesleukin The serum concentration of Ubidecarenone can be increased when it is combined with Aldesleukin. Approved Algeldrate The serum concentration of Ubidecarenone can be decreased when it is combined with Algeldrate. Experimental Almagate The serum concentration of Ubidecarenone can be decreased when it is combined with Almagate. Experimental Almasilate The serum concentration of Ubidecarenone can be decreased when it is combined with Almasilate. Experimental Aloglutamol The serum concentration of Ubidecarenone can be decreased when it is combined with Aloglutamol. Experimental Alprazolam The serum concentration of Ubidecarenone can be increased when it is combined with Alprazolam. Approved, Illicit, Investigational Aluminium The serum concentration of Ubidecarenone can be decreased when it is combined with Aluminium. Approved Aluminium acetoacetate The serum concentration of Ubidecarenone can be decreased when it is combined with Aluminium acetoacetate. Experimental Aluminium glycinate The serum concentration of Ubidecarenone can be decreased when it is combined with Aluminium glycinate. Experimental Aluminum hydroxide The serum concentration of Ubidecarenone can be decreased when it is combined with Aluminum hydroxide. Approved Ambroxol The serum concentration of Ubidecarenone can be increased when it is combined with Ambroxol. Approved Amiodarone The metabolism of Ubidecarenone can be decreased when combined with Amiodarone. Approved, Investigational Amlodipine The serum concentration of Ubidecarenone can be increased when it is combined with Amlodipine. Approved Amprenavir The serum concentration of Ubidecarenone can be increased when it is combined with Amprenavir. Approved Amrinone The risk or severity of adverse effects can be increased when Amrinone is combined with Ubidecarenone. Approved Anastrozole The serum concentration of Ubidecarenone can be increased when it is combined with Anastrozole. Approved, Investigational Antipyrine The serum concentration of Ubidecarenone can be increased when it is combined with Antipyrine. Approved Aprepitant The serum concentration of Ubidecarenone can be increased when it is combined with Aprepitant. Approved, Investigational Arsenic trioxide The serum concentration of Ubidecarenone can be increased when it is combined with Arsenic trioxide. Approved, Investigational Astemizole The serum concentration of Ubidecarenone can be increased when it is combined with Astemizole. Approved, Withdrawn Atazanavir The serum concentration of Ubidecarenone can be increased when it is combined with Atazanavir. Approved, Investigational Atomoxetine The serum concentration of Ubidecarenone can be increased when it is combined with Atomoxetine. Approved Atorvastatin The serum concentration of Ubidecarenone can be increased when it is combined with Atorvastatin. Approved Azelastine The serum concentration of Ubidecarenone can be increased when it is combined with Azelastine. Approved Azelnidipine The risk or severity of adverse effects can be increased when Azelnidipine is combined with Ubidecarenone. Approved Azimilide The risk or severity of adverse effects can be increased when Azimilide is combined with Ubidecarenone. Investigational Azithromycin The serum concentration of Ubidecarenone can be increased when it is combined with Azithromycin. Approved Barnidipine The risk or severity of adverse effects can be increased when Barnidipine is combined with Ubidecarenone. Approved Bencyclane The risk or severity of adverse effects can be increased when Bencyclane is combined with Ubidecarenone. Experimental Benidipine The risk or severity of adverse effects can be increased when Benidipine is combined with Ubidecarenone. Approved Bepridil The risk or severity of adverse effects can be increased when Bepridil is combined with Ubidecarenone. Approved, Withdrawn Betamethasone The serum concentration of Ubidecarenone can be increased when it is combined with Betamethasone. Approved, Vet Approved Bezafibrate Bezafibrate may increase the myopathic rhabdomyolysis activities of Ubidecarenone. Approved Bicalutamide The serum concentration of Ubidecarenone can be increased when it is combined with Bicalutamide. Approved Bifonazole The serum concentration of Ubidecarenone can be increased when it is combined with Bifonazole. Approved Bismuth Subcitrate The serum concentration of Ubidecarenone can be decreased when it is combined with Bismuth Subcitrate. Approved Bismuth subnitrate The serum concentration of Ubidecarenone can be decreased when it is combined with Bismuth subnitrate. Experimental Boceprevir The serum concentration of Ubidecarenone can be increased when it is combined with Boceprevir. Withdrawn Bortezomib The serum concentration of Ubidecarenone can be increased when it is combined with Bortezomib. Approved, Investigational Bosentan The metabolism of Ubidecarenone can be increased when combined with Bosentan. Approved, Investigational Brentuximab vedotin The serum concentration of Ubidecarenone can be increased when it is combined with Brentuximab vedotin. Approved Bromocriptine The serum concentration of Ubidecarenone can be increased when it is combined with Bromocriptine. Approved, Investigational Buprenorphine The serum concentration of Ubidecarenone can be increased when it is combined with Buprenorphine. Approved, Illicit, Investigational, Vet Approved Butoconazole The risk or severity of adverse effects can be increased when Butoconazole is combined with Ubidecarenone. Approved Cabergoline The serum concentration of Ubidecarenone can be increased when it is combined with Cabergoline. Approved Caffeine The serum concentration of Ubidecarenone can be increased when it is combined with Caffeine. Approved Calcium Carbonate The serum concentration of Ubidecarenone can be decreased when it is combined with Calcium Carbonate. Approved Calcium silicate The serum concentration of Ubidecarenone can be decreased when it is combined with Calcium silicate. Experimental Capsaicin The serum concentration of Ubidecarenone can be increased when it is combined with Capsaicin. Approved Carbomycin The risk or severity of adverse effects can be increased when Carbomycin is combined with Ubidecarenone. Vet Approved Carboxyamidotriazole The risk or severity of adverse effects can be increased when Carboxyamidotriazole is combined with Ubidecarenone. Investigational Caroverine The risk or severity of adverse effects can be increased when Caroverine is combined with Ubidecarenone. Experimental Caspofungin The serum concentration of Ubidecarenone can be increased when it is combined with Caspofungin. Approved Ceritinib The serum concentration of Ubidecarenone can be increased when it is combined with Ceritinib. Approved Cerivastatin The serum concentration of Ubidecarenone can be increased when it is combined with Cerivastatin. Withdrawn Chloramphenicol The serum concentration of Ubidecarenone can be increased when it is combined with Chloramphenicol. Approved, Vet Approved Chlorzoxazone The serum concentration of Ubidecarenone can be increased when it is combined with Chlorzoxazone. Approved Cilnidipine The risk or severity of adverse effects can be increased when Cilnidipine is combined with Ubidecarenone. Approved Cilostazol The serum concentration of Ubidecarenone can be increased when it is combined with Cilostazol. Approved Cimetidine The serum concentration of Ubidecarenone can be increased when it is combined with Cimetidine. Approved Cinnarizine The risk or severity of adverse effects can be increased when Cinnarizine is combined with Ubidecarenone. Approved Ciprofibrate The risk or severity of adverse effects can be increased when Ciprofibrate is combined with Ubidecarenone. Approved Ciprofloxacin The serum concentration of Ubidecarenone can be increased when it is combined with Ciprofloxacin. Approved, Investigational Cisapride The serum concentration of Ubidecarenone can be increased when it is combined with Cisapride. Approved, Investigational, Withdrawn Clarithromycin The serum concentration of Ubidecarenone can be increased when it is combined with Clarithromycin. Approved Clemastine The serum concentration of Ubidecarenone can be increased when it is combined with Clemastine. Approved Clevidipine The risk or severity of adverse effects can be increased when Clevidipine is combined with Ubidecarenone. Approved Clindamycin The serum concentration of Ubidecarenone can be increased when it is combined with Clindamycin. Approved, Vet Approved Clofazimine The serum concentration of Ubidecarenone can be increased when it is combined with Clofazimine. Approved, Investigational Clomifene The serum concentration of Ubidecarenone can be increased when it is combined with Clomifene. Approved, Investigational Clorindione Ubidecarenone may decrease the anticoagulant activities of Clorindione. Experimental Clotiazepam The serum concentration of Ubidecarenone can be increased when it is combined with Clotiazepam. Approved, Illicit Clotrimazole The serum concentration of Ubidecarenone can be increased when it is combined with Clotrimazole. Approved, Vet Approved Clozapine The serum concentration of Ubidecarenone can be increased when it is combined with Clozapine. Approved Cobicistat The serum concentration of Ubidecarenone can be increased when it is combined with Cobicistat. Approved Cocaine The serum concentration of Ubidecarenone can be increased when it is combined with Cocaine. Approved, Illicit Colchicine Colchicine may increase the myopathic rhabdomyolysis activities of Ubidecarenone. Approved Conivaptan The serum concentration of Ubidecarenone can be increased when it is combined with Conivaptan. Approved, Investigational Cortisone acetate The serum concentration of Ubidecarenone can be increased when it is combined with Cortisone acetate. Approved Crizotinib The serum concentration of Ubidecarenone can be increased when it is combined with Crizotinib. Approved Cyclophosphamide The serum concentration of Ubidecarenone can be increased when it is combined with Cyclophosphamide. Approved, Investigational Cyclosporine The serum concentration of Ubidecarenone can be increased when it is combined with Cyclosporine. Approved, Investigational, Vet Approved Cyproterone acetate The serum concentration of Ubidecarenone can be increased when it is combined with Cyproterone acetate. Approved, Investigational Daclatasvir The serum concentration of Ubidecarenone can be increased when it is combined with Daclatasvir. Approved Dalfopristin The serum concentration of Ubidecarenone can be increased when it is combined with Dalfopristin. Approved Danazol The serum concentration of Ubidecarenone can be increased when it is combined with Danazol. Approved Daptomycin The risk or severity of adverse effects can be increased when Ubidecarenone is combined with Daptomycin. Approved, Investigational Darodipine The risk or severity of adverse effects can be increased when Darodipine is combined with Ubidecarenone. Experimental Darunavir The serum concentration of Ubidecarenone can be increased when it is combined with Darunavir. Approved Dasatinib The serum concentration of Ubidecarenone can be increased when it is combined with Dasatinib. Approved, Investigational Daunorubicin The serum concentration of Ubidecarenone can be increased when it is combined with Daunorubicin. Approved Delavirdine The serum concentration of Ubidecarenone can be increased when it is combined with Delavirdine. Approved Desipramine The serum concentration of Ubidecarenone can be increased when it is combined with Desipramine. Approved Dexamethasone The serum concentration of Ubidecarenone can be increased when it is combined with Dexamethasone. Approved, Investigational, Vet Approved Dextropropoxyphene The serum concentration of Ubidecarenone can be increased when it is combined with Dextropropoxyphene. Approved, Illicit, Withdrawn Diazepam The serum concentration of Ubidecarenone can be increased when it is combined with Diazepam. Approved, Illicit, Vet Approved Dicoumarol Ubidecarenone may decrease the anticoagulant activities of Dicoumarol. Approved Diethylstilbestrol The serum concentration of Ubidecarenone can be increased when it is combined with Diethylstilbestrol. Approved Dihydroergotamine The serum concentration of Ubidecarenone can be increased when it is combined with Dihydroergotamine. Approved Diltiazem The serum concentration of Ubidecarenone can be increased when it is combined with Diltiazem. Approved Dimethyl sulfoxide The serum concentration of Ubidecarenone can be increased when it is combined with Dimethyl sulfoxide. Approved, Vet Approved Diphenadione Ubidecarenone may decrease the anticoagulant activities of Diphenadione. Experimental Docetaxel The serum concentration of Ubidecarenone can be increased when it is combined with Docetaxel. Approved, Investigational Dotarizine The risk or severity of adverse effects can be increased when Dotarizine is combined with Ubidecarenone. Investigational Doxorubicin The serum concentration of Ubidecarenone can be increased when it is combined with Doxorubicin. Approved, Investigational Doxycycline The serum concentration of Ubidecarenone can be increased when it is combined with Doxycycline. Approved, Investigational, Vet Approved Dronedarone The serum concentration of Ubidecarenone can be increased when it is combined with Dronedarone. Approved Econazole The serum concentration of Ubidecarenone can be increased when it is combined with Econazole. Approved Efavirenz The serum concentration of Ubidecarenone can be increased when it is combined with Efavirenz. Approved, Investigational Efinaconazole The risk or severity of adverse effects can be increased when Efinaconazole is combined with Ubidecarenone. Approved Efonidipine The risk or severity of adverse effects can be increased when Efonidipine is combined with Ubidecarenone. Approved Elbasvir The serum concentration of Ubidecarenone can be increased when it is combined with Elbasvir. Approved Enasidenib The serum concentration of Ubidecarenone can be increased when it is combined with Enasidenib. Approved Eperisone The risk or severity of adverse effects can be increased when Eperisone is combined with Ubidecarenone. Approved, Investigational Epinephrine The serum concentration of Ubidecarenone can be increased when it is combined with Epinephrine. Approved, Vet Approved Ergoloid mesylate The serum concentration of Ubidecarenone can be increased when it is combined with Ergoloid mesylate. Approved Ergonovine The serum concentration of Ubidecarenone can be increased when it is combined with Ergonovine. Approved Ergotamine The serum concentration of Ubidecarenone can be increased when it is combined with Ergotamine. Approved Erythromycin The serum concentration of Ubidecarenone can be increased when it is combined with Erythromycin. Approved, Vet Approved Ethanol The serum concentration of Ubidecarenone can be increased when it is combined with Ethanol. Approved Ethyl biscoumacetate Ubidecarenone may decrease the anticoagulant activities of Ethyl biscoumacetate. Withdrawn Etoposide The serum concentration of Ubidecarenone can be increased when it is combined with Etoposide. Approved Etoricoxib The serum concentration of Ubidecarenone can be increased when it is combined with Etoricoxib. Approved, Investigational Etravirine The serum concentration of Ubidecarenone can be decreased when it is combined with Etravirine. Approved Ezetimibe The serum concentration of Ubidecarenone can be increased when it is combined with Ezetimibe. Approved Felodipine The serum concentration of Ubidecarenone can be increased when it is combined with Felodipine. Approved, Investigational Fendiline The risk or severity of adverse effects can be increased when Fendiline is combined with Ubidecarenone. Withdrawn Fenofibrate The risk or severity of adverse effects can be increased when Fenofibrate is combined with Ubidecarenone. Approved Fentanyl The serum concentration of Ubidecarenone can be increased when it is combined with Fentanyl. Approved, Illicit, Investigational, Vet Approved Fenticonazole The risk or severity of adverse effects can be increased when Fenticonazole is combined with Ubidecarenone. Experimental Fidaxomicin The risk or severity of adverse effects can be increased when Fidaxomicin is combined with Ubidecarenone. Approved Fluconazole The serum concentration of Ubidecarenone can be increased when it is combined with Fluconazole. Approved Fluindione Ubidecarenone may decrease the anticoagulant activities of Fluindione. Investigational Flunarizine The risk or severity of adverse effects can be increased when Flunarizine is combined with Ubidecarenone. Approved Fluoxetine The serum concentration of Ubidecarenone can be increased when it is combined with Fluoxetine. Approved, Vet Approved Fluticasone propionate The serum concentration of Ubidecarenone can be increased when it is combined with Fluticasone propionate. Approved Fluvastatin The serum concentration of Ubidecarenone can be increased when it is combined with Fluvastatin. Approved Fluvoxamine The serum concentration of Ubidecarenone can be increased when it is combined with Fluvoxamine. Approved, Investigational Fosamprenavir The serum concentration of Ubidecarenone can be increased when it is combined with Fosamprenavir. Approved Fosaprepitant The serum concentration of Ubidecarenone can be increased when it is combined with Fosaprepitant. Approved Fosphenytoin The serum concentration of Ubidecarenone can be decreased when it is combined with Fosphenytoin. Approved Fusidic Acid The risk or severity of adverse effects can be increased when Fusidic Acid is combined with Ubidecarenone. Approved Gabapentin The risk or severity of adverse effects can be increased when Gabapentin is combined with Ubidecarenone. Approved, Investigational Gallopamil The risk or severity of adverse effects can be increased when Gallopamil is combined with Ubidecarenone. Investigational Gemfibrozil The serum concentration of Ubidecarenone can be increased when it is combined with Gemfibrozil. Approved Glyburide The serum concentration of Ubidecarenone can be increased when it is combined with Glyburide. Approved Glycerol Phenylbutyrate The serum concentration of Ubidecarenone can be increased when it is combined with Glycerol Phenylbutyrate. Approved Haloperidol The serum concentration of Ubidecarenone can be increased when it is combined with Haloperidol. Approved Histamine The serum concentration of Ubidecarenone can be increased when it is combined with Histamine. Approved, Investigational Hydralazine The serum concentration of Ubidecarenone can be increased when it is combined with Hydralazine. Approved Hydrocortisone The serum concentration of Ubidecarenone can be increased when it is combined with Hydrocortisone. Approved, Vet Approved Hydrotalcite The serum concentration of Ubidecarenone can be decreased when it is combined with Hydrotalcite. Experimental Idelalisib The serum concentration of Ubidecarenone can be increased when it is combined with Idelalisib. Approved Ifosfamide The serum concentration of Ubidecarenone can be increased when it is combined with Ifosfamide. Approved Iloperidone The serum concentration of Ubidecarenone can be increased when it is combined with Iloperidone. Approved Imatinib The serum concentration of Ubidecarenone can be increased when it is combined with Imatinib. Approved Indinavir The serum concentration of Ubidecarenone can be increased when it is combined with Indinavir. Approved indisulam The serum concentration of Ubidecarenone can be increased when it is combined with indisulam. Investigational Irbesartan The serum concentration of Ubidecarenone can be increased when it is combined with Irbesartan. Approved, Investigational Irinotecan The serum concentration of Ubidecarenone can be increased when it is combined with Irinotecan. Approved, Investigational Isavuconazole The risk or severity of adverse effects can be increased when Isavuconazole is combined with Ubidecarenone. Approved Isavuconazonium The serum concentration of Ubidecarenone can be increased when it is combined with Isavuconazonium. Approved, Investigational Isoconazole The risk or severity of adverse effects can be increased when Isoconazole is combined with Ubidecarenone. Approved Isoniazid The serum concentration of Ubidecarenone can be increased when it is combined with Isoniazid. Approved Isradipine The serum concentration of Ubidecarenone can be increased when it is combined with Isradipine. Approved Itraconazole The serum concentration of Ubidecarenone can be increased when it is combined with Itraconazole. Approved, Investigational Ivacaftor The serum concentration of Ubidecarenone can be increased when it is combined with Ivacaftor. Approved Josamycin The serum concentration of Ubidecarenone can be increased when it is combined with Josamycin. Approved Ketazolam The serum concentration of Ubidecarenone can be increased when it is combined with Ketazolam. Approved Ketoconazole The serum concentration of Ubidecarenone can be increased when it is combined with Ketoconazole. Approved, Investigational Kitasamycin The risk or severity of adverse effects can be increased when Kitasamycin is combined with Ubidecarenone. Experimental Lacidipine The risk or severity of adverse effects can be increased when Lacidipine is combined with Ubidecarenone. Approved Lamotrigine The risk or severity of adverse effects can be increased when Lamotrigine is combined with Ubidecarenone. Approved, Investigational Lansoprazole The serum concentration of Ubidecarenone can be increased when it is combined with Lansoprazole. Approved, Investigational Lanthanum carbonate The serum concentration of Lanthanum carbonate can be decreased when it is combined with Ubidecarenone. Approved Lapatinib The serum concentration of Ubidecarenone can be increased when it is combined with Lapatinib. Approved, Investigational Lercanidipine The serum concentration of Ubidecarenone can be increased when it is combined with Lercanidipine. Approved, Investigational Levofloxacin The serum concentration of Ubidecarenone can be increased when it is combined with Levofloxacin. Approved, Investigational Levosalbutamol The serum concentration of Ubidecarenone can be increased when it is combined with Levosalbutamol. Approved Lidocaine The serum concentration of Ubidecarenone can be increased when it is combined with Lidocaine. Approved, Vet Approved Lidoflazine The risk or severity of adverse effects can be increased when Lidoflazine is combined with Ubidecarenone. Experimental Linagliptin The serum concentration of Ubidecarenone can be increased when it is combined with Linagliptin. Approved Lomitapide The serum concentration of Ubidecarenone can be increased when it is combined with Lomitapide. Approved Lomustine The serum concentration of Ubidecarenone can be increased when it is combined with Lomustine. Approved Lopinavir The serum concentration of Ubidecarenone can be increased when it is combined with Lopinavir. Approved Loratadine The serum concentration of Ubidecarenone can be increased when it is combined with Loratadine. Approved Losartan The serum concentration of Ubidecarenone can be increased when it is combined with Losartan. Approved Lovastatin The serum concentration of Ubidecarenone can be increased when it is combined with Lovastatin. Approved, Investigational Luliconazole The serum concentration of Ubidecarenone can be increased when it is combined with Luliconazole. Approved Lurasidone The serum concentration of Ubidecarenone can be increased when it is combined with Lurasidone. Approved Magaldrate The serum concentration of Ubidecarenone can be decreased when it is combined with Magaldrate. Withdrawn Magnesium Hydroxide The serum concentration of Ubidecarenone can be decreased when it is combined with Magnesium Hydroxide. Approved Magnesium oxide The serum concentration of Ubidecarenone can be decreased when it is combined with Magnesium oxide. Approved Magnesium peroxide The serum concentration of Ubidecarenone can be decreased when it is combined with Magnesium peroxide. Experimental Magnesium silicate The serum concentration of Ubidecarenone can be decreased when it is combined with Magnesium silicate. Experimental Magnesium Sulfate The risk or severity of adverse effects can be increased when Magnesium Sulfate is combined with Ubidecarenone. Approved, Vet Approved Magnesium Trisilicate The serum concentration of Ubidecarenone can be decreased when it is combined with Magnesium Trisilicate. Approved Manidipine The serum concentration of Ubidecarenone can be increased when it is combined with Manidipine. Approved Mefloquine The serum concentration of Ubidecarenone can be increased when it is combined with Mefloquine. Approved Mequitazine The serum concentration of Ubidecarenone can be increased when it is combined with Mequitazine. Approved Methadone The serum concentration of Ubidecarenone can be increased when it is combined with Methadone. Approved Methazolamide The serum concentration of Ubidecarenone can be increased when it is combined with Methazolamide. Approved Methimazole The serum concentration of Ubidecarenone can be increased when it is combined with Methimazole. Approved Methylergometrine The serum concentration of Ubidecarenone can be increased when it is combined with Methylergometrine. Approved Methylprednisolone The serum concentration of Ubidecarenone can be increased when it is combined with Methylprednisolone. Approved, Vet Approved Metronidazole The serum concentration of Ubidecarenone can be increased when it is combined with Metronidazole. Approved Metyrapone The serum concentration of Ubidecarenone can be increased when it is combined with Metyrapone. Approved Mibefradil The serum concentration of Ubidecarenone can be increased when it is combined with Mibefradil. Withdrawn Miconazole The serum concentration of Ubidecarenone can be increased when it is combined with Miconazole. Approved, Investigational, Vet Approved Midazolam The serum concentration of Ubidecarenone can be increased when it is combined with Midazolam. Approved, Illicit Mifepristone The serum concentration of Ubidecarenone can be increased when it is combined with Mifepristone. Approved, Investigational Mirtazapine The serum concentration of Ubidecarenone can be increased when it is combined with Mirtazapine. Approved Mitoxantrone The serum concentration of Ubidecarenone can be increased when it is combined with Mitoxantrone. Approved, Investigational Modafinil The serum concentration of Ubidecarenone can be increased when it is combined with Modafinil. Approved, Investigational Naftopidil The risk or severity of adverse effects can be increased when Naftopidil is combined with Ubidecarenone. Investigational Nefazodone The serum concentration of Ubidecarenone can be increased when it is combined with Nefazodone. Approved, Withdrawn Nelfinavir The serum concentration of Ubidecarenone can be increased when it is combined with Nelfinavir. Approved Netupitant The serum concentration of Ubidecarenone can be increased when it is combined with Netupitant. Approved Nevirapine The serum concentration of Ubidecarenone can be increased when it is combined with Nevirapine. Approved Niacin The risk or severity of adverse effects can be increased when Niacin is combined with Ubidecarenone. Approved, Investigational, Nutraceutical Nicardipine The serum concentration of Ubidecarenone can be increased when it is combined with Nicardipine. Approved Nicotinamide The risk or severity of adverse effects can be increased when Nicotinamide is combined with Ubidecarenone. Approved Nifedipine The serum concentration of Ubidecarenone can be increased when it is combined with Nifedipine. Approved Niguldipine The risk or severity of adverse effects can be increased when Niguldipine is combined with Ubidecarenone. Experimental Nilotinib The serum concentration of Ubidecarenone can be increased when it is combined with Nilotinib. Approved, Investigational Niludipine The risk or severity of adverse effects can be increased when Niludipine is combined with Ubidecarenone. Experimental Nilvadipine The serum concentration of Ubidecarenone can be increased when it is combined with Nilvadipine. Approved Nimesulide The risk or severity of adverse effects can be increased when Nimesulide is combined with Ubidecarenone. Approved, Withdrawn Nimodipine The risk or severity of adverse effects can be increased when Nimodipine is combined with Ubidecarenone. Approved Nisoldipine The serum concentration of Ubidecarenone can be increased when it is combined with Nisoldipine. Approved Nitrendipine The serum concentration of Ubidecarenone can be increased when it is combined with Nitrendipine. Approved Nitric Oxide The serum concentration of Ubidecarenone can be increased when it is combined with Nitric Oxide. Approved Norfloxacin The serum concentration of Ubidecarenone can be increased when it is combined with Norfloxacin. Approved Noscapine The serum concentration of Ubidecarenone can be increased when it is combined with Noscapine. Investigational Olanzapine The serum concentration of Ubidecarenone can be increased when it is combined with Olanzapine. Approved, Investigational Olaparib The serum concentration of Ubidecarenone can be increased when it is combined with Olaparib. Approved Oleandomycin The risk or severity of adverse effects can be increased when Oleandomycin is combined with Ubidecarenone. Vet Approved Omeprazole The serum concentration of Ubidecarenone can be increased when it is combined with Omeprazole. Approved, Investigational, Vet Approved Omoconazole The risk or severity of adverse effects can be increased when Omoconazole is combined with Ubidecarenone. Experimental Otilonium The risk or severity of adverse effects can be increased when Otilonium is combined with Ubidecarenone. Experimental Oxiconazole The risk or severity of adverse effects can be increased when Oxiconazole is combined with Ubidecarenone. Approved Oxybutynin The serum concentration of Ubidecarenone can be increased when it is combined with Oxybutynin. Approved, Investigational Oxymetholone The serum concentration of Ubidecarenone can be increased when it is combined with Oxymetholone. Approved, Illicit Paclitaxel The serum concentration of Ubidecarenone can be increased when it is combined with Paclitaxel. Approved, Vet Approved Palbociclib The serum concentration of Ubidecarenone can be increased when it is combined with Palbociclib. Approved Paramethasone The serum concentration of Ubidecarenone can be increased when it is combined with Paramethasone. Approved Pazopanib Ubidecarenone may increase the hepatotoxic activities of Pazopanib. Approved Pergolide The serum concentration of Ubidecarenone can be increased when it is combined with Pergolide. Approved, Vet Approved, Withdrawn Perhexiline The risk or severity of adverse effects can be increased when Perhexiline is combined with Ubidecarenone. Approved Phenelzine The serum concentration of Ubidecarenone can be increased when it is combined with Phenelzine. Approved Phenindione Ubidecarenone may decrease the anticoagulant activities of Phenindione. Approved Phenprocoumon Ubidecarenone may decrease the anticoagulant activities of Phenprocoumon. Approved Phenytoin The serum concentration of Ubidecarenone can be decreased when it is combined with Phenytoin. Approved, Vet Approved Pilocarpine The serum concentration of Ubidecarenone can be increased when it is combined with Pilocarpine. Approved Pimozide The serum concentration of Ubidecarenone can be increased when it is combined with Pimozide. Approved Pinaverium The risk or severity of adverse effects can be increased when Pinaverium is combined with Ubidecarenone. Approved Posaconazole The serum concentration of Ubidecarenone can be increased when it is combined with Posaconazole. Approved, Investigational, Vet Approved Pravastatin The serum concentration of Ubidecarenone can be increased when it is combined with Pravastatin. Approved Prednisolone The serum concentration of Ubidecarenone can be increased when it is combined with Prednisolone. Approved, Vet Approved Prednisone The serum concentration of Ubidecarenone can be increased when it is combined with Prednisone. Approved, Vet Approved Pregabalin The risk or severity of adverse effects can be increased when Pregabalin is combined with Ubidecarenone. Approved, Illicit, Investigational Prenylamine The risk or severity of adverse effects can be increased when Prenylamine is combined with Ubidecarenone. Withdrawn Primaquine The serum concentration of Ubidecarenone can be increased when it is combined with Primaquine. Approved Progesterone The serum concentration of Ubidecarenone can be increased when it is combined with Progesterone. Approved, Vet Approved Propofol The serum concentration of Ubidecarenone can be increased when it is combined with Propofol. Approved, Investigational, Vet Approved Quinidine The serum concentration of Ubidecarenone can be increased when it is combined with Quinidine. Approved Quinine The serum concentration of Ubidecarenone can be increased when it is combined with Quinine. Approved Quinupristin The serum concentration of Ubidecarenone can be increased when it is combined with Quinupristin. Approved Rabeprazole The serum concentration of Ubidecarenone can be increased when it is combined with Rabeprazole. Approved, Investigational Raloxifene The serum concentration of Ubidecarenone can be increased when it is combined with Raloxifene. Approved, Investigational Raltegravir Raltegravir may increase the myopathic rhabdomyolysis activities of Ubidecarenone. Approved Ranitidine The serum concentration of Ubidecarenone can be increased when it is combined with Ranitidine. Approved Ranolazine The serum concentration of Ubidecarenone can be increased when it is combined with Ranolazine. Approved, Investigational Ravuconazole The risk or severity of adverse effects can be increased when Ravuconazole is combined with Ubidecarenone. Investigational Regorafenib The serum concentration of Ubidecarenone can be increased when it is combined with Regorafenib. Approved Repaglinide The serum concentration of Ubidecarenone can be increased when it is combined with Repaglinide. Approved, Investigational Resveratrol The serum concentration of Ubidecarenone can be increased when it is combined with Resveratrol. Experimental, Investigational Rifabutin The serum concentration of Ubidecarenone can be decreased when it is combined with Rifabutin. Approved Rifampicin The serum concentration of Ubidecarenone can be decreased when it is combined with Rifampicin. Approved Rifapentine The serum concentration of Ubidecarenone can be decreased when it is combined with Rifapentine. Approved Rilpivirine The serum concentration of Ubidecarenone can be increased when it is combined with Rilpivirine. Approved Risedronate The risk or severity of adverse effects can be increased when Risedronate is combined with Ubidecarenone. Approved, Investigational Risperidone The serum concentration of Ubidecarenone can be increased when it is combined with Risperidone. Approved, Investigational Ritonavir The serum concentration of Ubidecarenone can be increased when it is combined with Ritonavir. Approved, Investigational Rivastigmine The serum concentration of Ubidecarenone can be increased when it is combined with Rivastigmine. Approved, Investigational Rolitetracycline The serum concentration of Ubidecarenone can be increased when it is combined with Rolitetracycline. Approved Rosuvastatin The serum concentration of Ubidecarenone can be increased when it is combined with Rosuvastatin. Approved Roxithromycin The serum concentration of Ubidecarenone can be increased when it is combined with Roxithromycin. Approved, Withdrawn Rutin The serum concentration of Ubidecarenone can be increased when it is combined with Rutin. Experimental Salbutamol The serum concentration of Ubidecarenone can be increased when it is combined with Salbutamol. Approved, Vet Approved Saquinavir The serum concentration of Ubidecarenone can be increased when it is combined with Saquinavir. Approved, Investigational Sarilumab The serum concentration of Ubidecarenone can be increased when it is combined with Sarilumab. Approved Sertaconazole The risk or severity of adverse effects can be increased when Sertaconazole is combined with Ubidecarenone. Approved Sertraline The serum concentration of Ubidecarenone can be increased when it is combined with Sertraline. Approved Sildenafil The serum concentration of Ubidecarenone can be increased when it is combined with Sildenafil. Approved, Investigational Simeprevir The serum concentration of Ubidecarenone can be increased when it is combined with Simeprevir. Approved Simvastatin The serum concentration of Ubidecarenone can be increased when it is combined with Simvastatin. Approved Sirolimus The serum concentration of Ubidecarenone can be increased when it is combined with Sirolimus. Approved, Investigational Sitaxentan The serum concentration of Ubidecarenone can be increased when it is combined with Sitaxentan. Approved, Investigational, Withdrawn Solithromycin The risk or severity of adverse effects can be increased when Solithromycin is combined with Ubidecarenone. Investigational Sorafenib The serum concentration of Ubidecarenone can be increased when it is combined with Sorafenib. Approved, Investigational Spiramycin The risk or severity of adverse effects can be increased when Spiramycin is combined with Ubidecarenone. Approved St. John's Wort The metabolism of Ubidecarenone can be increased when combined with St. John's Wort. Nutraceutical Stiripentol The serum concentration of Ubidecarenone can be increased when it is combined with Stiripentol. Approved Sulconazole The risk or severity of adverse effects can be increased when Sulconazole is combined with Ubidecarenone. Approved Sulfamethoxazole The serum concentration of Ubidecarenone can be increased when it is combined with Sulfamethoxazole. Approved Sulfanilamide The serum concentration of Ubidecarenone can be increased when it is combined with Sulfanilamide. Approved Sulfinpyrazone The serum concentration of Ubidecarenone can be increased when it is combined with Sulfinpyrazone. Approved Sulfisoxazole The serum concentration of Ubidecarenone can be increased when it is combined with Sulfisoxazole. Approved, Vet Approved Tacrolimus The serum concentration of Ubidecarenone can be increased when it is combined with Tacrolimus. Approved, Investigational Tadalafil The serum concentration of Ubidecarenone can be increased when it is combined with Tadalafil. Approved, Investigational Tamoxifen The serum concentration of Ubidecarenone can be increased when it is combined with Tamoxifen. Approved Telaprevir The serum concentration of Ubidecarenone can be increased when it is combined with Telaprevir. Withdrawn Telithromycin The serum concentration of Ubidecarenone can be increased when it is combined with Telithromycin. Approved Temsirolimus The serum concentration of Ubidecarenone can be increased when it is combined with Temsirolimus. Approved Teniposide The serum concentration of Ubidecarenone can be increased when it is combined with Teniposide. Approved Terconazole The risk or severity of adverse effects can be increased when Terconazole is combined with Ubidecarenone. Approved Terfenadine The serum concentration of Ubidecarenone can be increased when it is combined with Terfenadine. Withdrawn Terodiline The risk or severity of adverse effects can be increased when Terodiline is combined with Ubidecarenone. Experimental Tesmilifene The serum concentration of Ubidecarenone can be increased when it is combined with Tesmilifene. Investigational Testosterone The serum concentration of Ubidecarenone can be increased when it is combined with Testosterone. Approved, Investigational Tetracycline The serum concentration of Ubidecarenone can be increased when it is combined with Tetracycline. Approved, Vet Approved Tetrahydropalmatine The risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with Ubidecarenone. Investigational Thiopental The serum concentration of Ubidecarenone can be increased when it is combined with Thiopental. Approved, Vet Approved Ticagrelor The serum concentration of Ubidecarenone can be increased when it is combined with Ticagrelor. Approved Ticlopidine The serum concentration of Ubidecarenone can be increased when it is combined with Ticlopidine. Approved Tioclomarol Ubidecarenone may decrease the anticoagulant activities of Tioclomarol. Experimental Tioconazole The serum concentration of Ubidecarenone can be increased when it is combined with Tioconazole. Approved Tipranavir The serum concentration of Ubidecarenone can be increased when it is combined with Tipranavir. Approved, Investigational Tofisopam The serum concentration of Ubidecarenone can be increased when it is combined with Tofisopam. Approved Tolfenamic Acid The risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Ubidecarenone. Approved Topiroxostat The serum concentration of Ubidecarenone can be increased when it is combined with Topiroxostat. Approved Topotecan The serum concentration of Ubidecarenone can be increased when it is combined with Topotecan. Approved, Investigational Trabectedin Ubidecarenone may increase the myopathic rhabdomyolysis activities of Trabectedin. Approved, Investigational Tramadol The serum concentration of Ubidecarenone can be increased when it is combined with Tramadol. Approved, Investigational Tranilast The risk or severity of adverse effects can be increased when Tranilast is combined with Ubidecarenone. Approved, Investigational Tranylcypromine The serum concentration of Ubidecarenone can be increased when it is combined with Tranylcypromine. Approved Troglitazone The serum concentration of Ubidecarenone can be increased when it is combined with Troglitazone. Withdrawn Troleandomycin The serum concentration of Ubidecarenone can be increased when it is combined with Troleandomycin. Approved Tylosin The risk or severity of adverse effects can be increased when Tylosin is combined with Ubidecarenone. Vet Approved Valproic Acid The serum concentration of Ubidecarenone can be increased when it is combined with Valproic Acid. Approved, Investigational Venlafaxine The serum concentration of Ubidecarenone can be increased when it is combined with Venlafaxine. Approved Verapamil The serum concentration of Ubidecarenone can be increased when it is combined with Verapamil. Approved Vinblastine The serum concentration of Ubidecarenone can be increased when it is combined with Vinblastine. Approved Vincristine The serum concentration of Ubidecarenone can be increased when it is combined with Vincristine. Approved, Investigational Vinorelbine The serum concentration of Ubidecarenone can be increased when it is combined with Vinorelbine. Approved, Investigational Vinpocetine The risk or severity of adverse effects can be increased when Vinpocetine is combined with Ubidecarenone. Investigational Voriconazole The serum concentration of Ubidecarenone can be increased when it is combined with Voriconazole. Approved, Investigational Warfarin Ubidecarenone may decrease the anticoagulant activities of Warfarin. Approved Xylometazoline The risk or severity of adverse effects can be increased when Xylometazoline is combined with Ubidecarenone. Approved Zafirlukast The serum concentration of Ubidecarenone can be increased when it is combined with Zafirlukast. Approved, Investigational Ziconotide The risk or severity of adverse effects can be increased when Ziconotide is combined with Ubidecarenone. Approved Ziprasidone The serum concentration of Ubidecarenone can be increased when it is combined with Ziprasidone. Approved Zucapsaicin The serum concentration of Ubidecarenone can be increased when it is combined with Zucapsaicin. Approved - Food Interactions
- Not Available
References
- General References
- Ernster L, Dallner G: Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta. 1995 May 24;1271(1):195-204. [PubMed:7599208]
- External Links
- Human Metabolome Database
- HMDB01072
- KEGG Drug
- D01065
- KEGG Compound
- C11378
- PubChem Compound
- 5281915
- PubChem Substance
- 310265165
- ChemSpider
- 4445197
- ChEBI
- 46245
- ChEMBL
- CHEMBL454801
- HET
- U10
- Wikipedia
- Coenzyme_Q10
- ATC Codes
- C01EB09 — Ubidecarenone
- AHFS Codes
- 88:29.00* — Minerals
- 88:28.00 — Multivitamin Preparations
- 88:30.00* — Other Nutritional Agents
- 88:20.00 — Vitamin E
- 88:28.01* — Vitamins & Minerals
- PDB Entries
- 1aig / 1aij / 1bcc / 1ds8 / 1dv3 / 1dv6 / 1e14 / 1e6d / 1f6n / 1fnp … show 93 more
- MSDS
- Download (92.4 KB)
Clinical Trials
- Clinical Trials
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage forms
Form Route Strength Capsule Oral 50 mg Capsule Oral 100 mg Solution Oral Tablet Oral 10 mg Capsule Oral 50.0 mg Capsule Oral 12 mg Tablet Oral 100 mg Capsule Oral 60 mg Capsule Oral 80 mg Capsule Oral 15 mg Capsule Oral 30 mg Powder Oral Capsule Oral 10 mg Tablet Oral Capsule Oral Tablet Oral 60 mg Capsule Oral 25 mg Capsule Oral 20 mg - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 50-52 MSDS water solubility Insoluble MSDS - Predicted Properties
Property Value Source Water Solubility 0.000193 mg/mL ALOGPS logP 9.94 ALOGPS logP 17.16 ChemAxon logS -6.6 ALOGPS pKa (Strongest Basic) -4.7 ChemAxon Physiological Charge 0 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 0 ChemAxon Polar Surface Area 52.6 Å2 ChemAxon Rotatable Bond Count 31 ChemAxon Refractivity 286.61 m3·mol-1 ChemAxon Polarizability 112.38 Å3 ChemAxon Number of Rings 1 ChemAxon Bioavailability 0 ChemAxon Rule of Five No ChemAxon Ghose Filter No ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Taxonomy
- Description
- This compound belongs to the class of organic compounds known as ubiquinones. These are coenzyme Q derivatives containing a 5, 6-dimethoxy-3-methyl(1,4-benzoquinone) moiety to which an isoprenyl group is attached at ring position 2(or 6).
- Kingdom
- Organic compounds
- Super Class
- Lipids and lipid-like molecules
- Class
- Prenol lipids
- Sub Class
- Quinone and hydroquinone lipids
- Direct Parent
- Ubiquinones
- Alternative Parents
- Polyterpenoids / Polyprenylbenzoquinones / P-benzoquinones / Vinylogous esters / Organic oxides / Hydrocarbon derivatives
- Substituents
- Polyterpenoid / Polyprenylbenzoquinone / Ubiquinone skeleton / Quinone / P-benzoquinone / Vinylogous ester / Cyclic ketone / Ketone / Organic oxygen compound / Organic oxide
- Molecular Framework
- Aliphatic homomonocyclic compounds
- External Descriptors
- ubiquinones (CHEBI:46245) / ubiquinones, Coenzymes (C11378) / Ubiquinones (LMPR02010001)
Drug created on October 28, 2015 09:41 / Updated on October 21, 2017 19:33